Active, not recruitingPhase 2NCT04870866

NAD Supplementation to Prevent Progressive Neurological Disease in Ataxia Telangiectasia

Studying Ataxia-telangiectasia

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University Hospital, Akershus
Principal Investigator
Hilde L Nilsen
University Hospital, Akershus
Intervention
Nicotinamide ribonucleoside(drug)
Enrollment
13 enrolled
Eligibility
3 years · All sexes
Timeline
2019 – 2027

Study locations (2)

Collaborators

The Bergesen Foundation · South-Eastern Norway Regional Health Authority · Sykehuset Innlandet HF · Oslo University Hospital · St. Olavs Hospital · Haukeland University Hospital · University Hospital of North Norway · University of Bergen

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04870866 on ClinicalTrials.gov

Other trials for Ataxia-telangiectasia

Additional recruiting or active studies for the same condition.

See all trials for Ataxia-telangiectasia →

← Back to all trials